nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—liver cancer	0.336	1	CbGaD
Bortezomib—CYP2C8—Sorafenib—liver cancer	0.0263	0.2	CbGbCtD
Bortezomib—CYP2C19—Sorafenib—liver cancer	0.0221	0.168	CbGbCtD
Bortezomib—CYP1A2—Sorafenib—liver cancer	0.0204	0.155	CbGbCtD
Bortezomib—CYP2C9—Sorafenib—liver cancer	0.0184	0.14	CbGbCtD
Bortezomib—CYP2D6—Sorafenib—liver cancer	0.0168	0.128	CbGbCtD
Bortezomib—CYP3A4—Sorafenib—liver cancer	0.0107	0.0813	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—liver cancer	0.0102	0.0776	CbGbCtD
Bortezomib—CYP3A4—Doxorubicin—liver cancer	0.00648	0.0493	CbGbCtD
Bortezomib—PSMA1—embryo—liver cancer	0.00358	0.168	CbGeAlD
Bortezomib—PSMD2—embryo—liver cancer	0.00267	0.125	CbGeAlD
Bortezomib—PSMB1—embryo—liver cancer	0.00205	0.0956	CbGeAlD
Bortezomib—PSMB2—embryo—liver cancer	0.002	0.0933	CbGeAlD
Bortezomib—PSMA1—liver—liver cancer	0.00166	0.0775	CbGeAlD
Bortezomib—PSMD1—liver—liver cancer	0.00139	0.0651	CbGeAlD
Bortezomib—PSMD2—liver—liver cancer	0.00123	0.0576	CbGeAlD
Bortezomib—PSMB8—liver—liver cancer	0.00123	0.0573	CbGeAlD
Bortezomib—PSMB5—liver—liver cancer	0.00108	0.0506	CbGeAlD
Bortezomib—PSMB1—liver—liver cancer	0.000946	0.0442	CbGeAlD
Bortezomib—PSMB2—liver—liver cancer	0.000923	0.0432	CbGeAlD
Bortezomib—SLC31A1—liver—liver cancer	0.000799	0.0374	CbGeAlD
Bortezomib—Nateglinide—PPARG—liver cancer	0.000472	0.727	CrCbGaD
Bortezomib—CYP2C19—liver—liver cancer	0.000337	0.0158	CbGeAlD
Bortezomib—CYP2C8—liver—liver cancer	0.000294	0.0138	CbGeAlD
Bortezomib—CYP1A2—liver—liver cancer	0.000275	0.0129	CbGeAlD
Bortezomib—CYP1A1—liver—liver cancer	0.000271	0.0127	CbGeAlD
Bortezomib—CYP2C9—liver—liver cancer	0.000261	0.0122	CbGeAlD
Bortezomib—CYP3A4—liver—liver cancer	0.000199	0.00932	CbGeAlD
Bortezomib—CYP2D6—liver—liver cancer	0.000196	0.00917	CbGeAlD
Bortezomib—Nateglinide—ALB—liver cancer	0.000178	0.273	CrCbGaD
Bortezomib—Dry skin—Epirubicin—liver cancer	0.000148	0.000665	CcSEcCtD
Bortezomib—Orthostatic hypotension—Epirubicin—liver cancer	0.000148	0.000662	CcSEcCtD
Bortezomib—Abdominal pain upper—Epirubicin—liver cancer	0.000148	0.000662	CcSEcCtD
Bortezomib—Migraine—Doxorubicin—liver cancer	0.000147	0.00066	CcSEcCtD
Bortezomib—Hypokalaemia—Epirubicin—liver cancer	0.000147	0.00066	CcSEcCtD
Bortezomib—Diarrhoea—Sorafenib—liver cancer	0.000147	0.00066	CcSEcCtD
Bortezomib—Breast disorder—Epirubicin—liver cancer	0.000146	0.000655	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000146	0.000653	CcSEcCtD
Bortezomib—Nasopharyngitis—Epirubicin—liver cancer	0.000145	0.000649	CcSEcCtD
Bortezomib—Face oedema—Doxorubicin—liver cancer	0.000145	0.000648	CcSEcCtD
Bortezomib—Gastritis—Epirubicin—liver cancer	0.000143	0.000642	CcSEcCtD
Bortezomib—Muscular weakness—Epirubicin—liver cancer	0.000143	0.00064	CcSEcCtD
Bortezomib—Cardiac arrest—Doxorubicin—liver cancer	0.000142	0.000638	CcSEcCtD
Bortezomib—Dizziness—Sorafenib—liver cancer	0.000142	0.000638	CcSEcCtD
Bortezomib—Abdominal distension—Epirubicin—liver cancer	0.000141	0.000631	CcSEcCtD
Bortezomib—Ataxia—Doxorubicin—liver cancer	0.000141	0.000631	CcSEcCtD
Bortezomib—Influenza—Epirubicin—liver cancer	0.00014	0.000627	CcSEcCtD
Bortezomib—Dysphagia—Epirubicin—liver cancer	0.00014	0.000627	CcSEcCtD
Bortezomib—Dehydration—Doxorubicin—liver cancer	0.000139	0.000624	CcSEcCtD
Bortezomib—Dry skin—Doxorubicin—liver cancer	0.000137	0.000615	CcSEcCtD
Bortezomib—Pancreatitis—Epirubicin—liver cancer	0.000137	0.000615	CcSEcCtD
Bortezomib—Vomiting—Sorafenib—liver cancer	0.000137	0.000613	CcSEcCtD
Bortezomib—Abdominal pain upper—Doxorubicin—liver cancer	0.000137	0.000613	CcSEcCtD
Bortezomib—Orthostatic hypotension—Doxorubicin—liver cancer	0.000137	0.000613	CcSEcCtD
Bortezomib—Hypokalaemia—Doxorubicin—liver cancer	0.000136	0.000611	CcSEcCtD
Bortezomib—Angina pectoris—Epirubicin—liver cancer	0.000136	0.000611	CcSEcCtD
Bortezomib—Rash—Sorafenib—liver cancer	0.000136	0.000608	CcSEcCtD
Bortezomib—Dermatitis—Sorafenib—liver cancer	0.000136	0.000608	CcSEcCtD
Bortezomib—Breast disorder—Doxorubicin—liver cancer	0.000135	0.000606	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000135	0.000604	CcSEcCtD
Bortezomib—Headache—Sorafenib—liver cancer	0.000135	0.000604	CcSEcCtD
Bortezomib—Bronchitis—Epirubicin—liver cancer	0.000134	0.000603	CcSEcCtD
Bortezomib—Nasopharyngitis—Doxorubicin—liver cancer	0.000134	0.0006	CcSEcCtD
Bortezomib—Pancytopenia—Epirubicin—liver cancer	0.000133	0.000595	CcSEcCtD
Bortezomib—Gastritis—Doxorubicin—liver cancer	0.000132	0.000594	CcSEcCtD
Bortezomib—Muscular weakness—Doxorubicin—liver cancer	0.000132	0.000592	CcSEcCtD
Bortezomib—Neutropenia—Epirubicin—liver cancer	0.000131	0.000586	CcSEcCtD
Bortezomib—Abdominal distension—Doxorubicin—liver cancer	0.00013	0.000584	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Epirubicin—liver cancer	0.00013	0.000583	CcSEcCtD
Bortezomib—Dysphagia—Doxorubicin—liver cancer	0.000129	0.00058	CcSEcCtD
Bortezomib—Influenza—Doxorubicin—liver cancer	0.000129	0.00058	CcSEcCtD
Bortezomib—Pollakiuria—Epirubicin—liver cancer	0.000129	0.000579	CcSEcCtD
Bortezomib—Nausea—Sorafenib—liver cancer	0.000128	0.000573	CcSEcCtD
Bortezomib—Photosensitivity reaction—Epirubicin—liver cancer	0.000128	0.000572	CcSEcCtD
Bortezomib—Weight increased—Epirubicin—liver cancer	0.000127	0.00057	CcSEcCtD
Bortezomib—Pancreatitis—Doxorubicin—liver cancer	0.000127	0.000569	CcSEcCtD
Bortezomib—Weight decreased—Epirubicin—liver cancer	0.000127	0.000567	CcSEcCtD
Bortezomib—Hyperglycaemia—Epirubicin—liver cancer	0.000126	0.000565	CcSEcCtD
Bortezomib—Angina pectoris—Doxorubicin—liver cancer	0.000126	0.000565	CcSEcCtD
Bortezomib—Pneumonia—Epirubicin—liver cancer	0.000125	0.000562	CcSEcCtD
Bortezomib—Infestation—Epirubicin—liver cancer	0.000125	0.000559	CcSEcCtD
Bortezomib—Infestation NOS—Epirubicin—liver cancer	0.000125	0.000559	CcSEcCtD
Bortezomib—Bronchitis—Doxorubicin—liver cancer	0.000124	0.000558	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000124	0.000554	CcSEcCtD
Bortezomib—Pancytopenia—Doxorubicin—liver cancer	0.000123	0.000551	CcSEcCtD
Bortezomib—Renal failure—Epirubicin—liver cancer	0.000123	0.000549	CcSEcCtD
Bortezomib—Neuropathy peripheral—Epirubicin—liver cancer	0.000122	0.000548	CcSEcCtD
Bortezomib—Stomatitis—Epirubicin—liver cancer	0.000122	0.000545	CcSEcCtD
Bortezomib—Urinary tract infection—Epirubicin—liver cancer	0.000121	0.000543	CcSEcCtD
Bortezomib—Conjunctivitis—Epirubicin—liver cancer	0.000121	0.000543	CcSEcCtD
Bortezomib—Neutropenia—Doxorubicin—liver cancer	0.000121	0.000542	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00012	0.000539	CcSEcCtD
Bortezomib—Pollakiuria—Doxorubicin—liver cancer	0.00012	0.000536	CcSEcCtD
Bortezomib—Haematuria—Epirubicin—liver cancer	0.000119	0.000533	CcSEcCtD
Bortezomib—Photosensitivity reaction—Doxorubicin—liver cancer	0.000118	0.000529	CcSEcCtD
Bortezomib—Hepatobiliary disease—Epirubicin—liver cancer	0.000118	0.000529	CcSEcCtD
Bortezomib—Weight increased—Doxorubicin—liver cancer	0.000118	0.000528	CcSEcCtD
Bortezomib—Epistaxis—Epirubicin—liver cancer	0.000118	0.000527	CcSEcCtD
Bortezomib—Weight decreased—Doxorubicin—liver cancer	0.000117	0.000525	CcSEcCtD
Bortezomib—Sinusitis—Epirubicin—liver cancer	0.000117	0.000524	CcSEcCtD
Bortezomib—Hyperglycaemia—Doxorubicin—liver cancer	0.000117	0.000523	CcSEcCtD
Bortezomib—Pneumonia—Doxorubicin—liver cancer	0.000116	0.00052	CcSEcCtD
Bortezomib—Infestation—Doxorubicin—liver cancer	0.000115	0.000517	CcSEcCtD
Bortezomib—Infestation NOS—Doxorubicin—liver cancer	0.000115	0.000517	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000114	0.000513	CcSEcCtD
Bortezomib—Bradycardia—Epirubicin—liver cancer	0.000114	0.000511	CcSEcCtD
Bortezomib—Renal failure—Doxorubicin—liver cancer	0.000113	0.000508	CcSEcCtD
Bortezomib—Neuropathy peripheral—Doxorubicin—liver cancer	0.000113	0.000507	CcSEcCtD
Bortezomib—Haemoglobin—Epirubicin—liver cancer	0.000112	0.000504	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—liver cancer	0.000112	0.000504	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—liver cancer	0.000112	0.000503	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—liver cancer	0.000112	0.000503	CcSEcCtD
Bortezomib—Hepatitis—Epirubicin—liver cancer	0.000112	0.000502	CcSEcCtD
Bortezomib—Haemorrhage—Epirubicin—liver cancer	0.000112	0.000502	CcSEcCtD
Bortezomib—Hypoaesthesia—Epirubicin—liver cancer	0.000111	0.000499	CcSEcCtD
Bortezomib—Urinary tract disorder—Epirubicin—liver cancer	0.000111	0.000495	CcSEcCtD
Bortezomib—Oedema peripheral—Epirubicin—liver cancer	0.00011	0.000494	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—liver cancer	0.00011	0.000493	CcSEcCtD
Bortezomib—Connective tissue disorder—Epirubicin—liver cancer	0.00011	0.000493	CcSEcCtD
Bortezomib—Urethral disorder—Epirubicin—liver cancer	0.00011	0.000492	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—liver cancer	0.000109	0.000489	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—liver cancer	0.000109	0.000488	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—liver cancer	0.000108	0.000485	CcSEcCtD
Bortezomib—Visual impairment—Epirubicin—liver cancer	0.000108	0.000483	CcSEcCtD
Bortezomib—Erythema multiforme—Epirubicin—liver cancer	0.000106	0.000474	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—liver cancer	0.000105	0.000473	CcSEcCtD
Bortezomib—Eye disorder—Epirubicin—liver cancer	0.000105	0.000469	CcSEcCtD
Bortezomib—Tinnitus—Epirubicin—liver cancer	0.000104	0.000468	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—liver cancer	0.000104	0.000467	CcSEcCtD
Bortezomib—Cardiac disorder—Epirubicin—liver cancer	0.000104	0.000466	CcSEcCtD
Bortezomib—Flushing—Epirubicin—liver cancer	0.000104	0.000466	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—liver cancer	0.000104	0.000464	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—liver cancer	0.000104	0.000464	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—liver cancer	0.000103	0.000462	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—liver cancer	0.000102	0.000458	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—liver cancer	0.000102	0.000457	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—liver cancer	0.000102	0.000456	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—liver cancer	0.000102	0.000455	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—liver cancer	0.000102	0.000455	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—liver cancer	0.000101	0.000453	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—liver cancer	0.000101	0.000452	CcSEcCtD
Bortezomib—Chills—Epirubicin—liver cancer	0.0001	0.00045	CcSEcCtD
Bortezomib—Arrhythmia—Epirubicin—liver cancer	0.0001	0.000448	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—liver cancer	9.98e-05	0.000447	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—liver cancer	9.81e-05	0.00044	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—liver cancer	9.79e-05	0.000439	CcSEcCtD
Bortezomib—Erythema—Epirubicin—liver cancer	9.74e-05	0.000437	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—liver cancer	9.74e-05	0.000437	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—liver cancer	9.68e-05	0.000434	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—liver cancer	9.66e-05	0.000433	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—liver cancer	9.61e-05	0.000431	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—liver cancer	9.61e-05	0.000431	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—liver cancer	9.6e-05	0.00043	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—liver cancer	9.54e-05	0.000428	CcSEcCtD
Bortezomib—Back pain—Epirubicin—liver cancer	9.42e-05	0.000422	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—liver cancer	9.4e-05	0.000421	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—liver cancer	9.37e-05	0.00042	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—liver cancer	9.35e-05	0.000419	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—liver cancer	9.33e-05	0.000418	CcSEcCtD
Bortezomib—Chills—Doxorubicin—liver cancer	9.29e-05	0.000417	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—liver cancer	9.25e-05	0.000415	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—liver cancer	9.18e-05	0.000412	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—liver cancer	9.07e-05	0.000407	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—liver cancer	9.04e-05	0.000405	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—liver cancer	9.02e-05	0.000404	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—liver cancer	9.02e-05	0.000404	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—liver cancer	9.01e-05	0.000404	CcSEcCtD
Bortezomib—Agitation—Epirubicin—liver cancer	8.95e-05	0.000401	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—liver cancer	8.88e-05	0.000398	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—liver cancer	8.83e-05	0.000396	CcSEcCtD
Bortezomib—Malaise—Epirubicin—liver cancer	8.79e-05	0.000394	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—liver cancer	8.75e-05	0.000392	CcSEcCtD
Bortezomib—Syncope—Epirubicin—liver cancer	8.74e-05	0.000392	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—liver cancer	8.72e-05	0.000391	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—liver cancer	8.72e-05	0.000391	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—liver cancer	8.67e-05	0.000389	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—liver cancer	8.61e-05	0.000386	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—liver cancer	8.56e-05	0.000384	CcSEcCtD
Bortezomib—Cough—Epirubicin—liver cancer	8.5e-05	0.000381	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—liver cancer	8.5e-05	0.000381	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—liver cancer	8.44e-05	0.000378	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—liver cancer	8.41e-05	0.000377	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—liver cancer	8.36e-05	0.000375	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—liver cancer	8.33e-05	0.000374	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—liver cancer	8.29e-05	0.000372	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—liver cancer	8.29e-05	0.000372	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—liver cancer	8.29e-05	0.000372	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—liver cancer	8.28e-05	0.000371	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—liver cancer	8.27e-05	0.000371	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	8.24e-05	0.000369	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—liver cancer	8.2e-05	0.000367	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—liver cancer	8.13e-05	0.000364	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—liver cancer	8.1e-05	0.000363	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—liver cancer	8.08e-05	0.000362	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—liver cancer	8.07e-05	0.000362	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—liver cancer	8.02e-05	0.000359	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—liver cancer	7.97e-05	0.000357	CcSEcCtD
Bortezomib—Oedema—Epirubicin—liver cancer	7.95e-05	0.000356	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—liver cancer	7.95e-05	0.000356	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—liver cancer	7.92e-05	0.000355	CcSEcCtD
Bortezomib—Infection—Epirubicin—liver cancer	7.9e-05	0.000354	CcSEcCtD
Bortezomib—Cough—Doxorubicin—liver cancer	7.87e-05	0.000353	CcSEcCtD
Bortezomib—Shock—Epirubicin—liver cancer	7.82e-05	0.000351	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—liver cancer	7.81e-05	0.00035	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—liver cancer	7.8e-05	0.00035	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—liver cancer	7.79e-05	0.000349	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—liver cancer	7.78e-05	0.000349	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—liver cancer	7.76e-05	0.000348	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—liver cancer	7.72e-05	0.000346	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—liver cancer	7.69e-05	0.000345	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—liver cancer	7.68e-05	0.000344	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—liver cancer	7.68e-05	0.000344	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—liver cancer	7.68e-05	0.000344	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—liver cancer	7.65e-05	0.000343	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	7.62e-05	0.000342	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—liver cancer	7.58e-05	0.00034	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—liver cancer	7.58e-05	0.00034	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—liver cancer	7.43e-05	0.000333	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—liver cancer	7.42e-05	0.000333	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—liver cancer	7.36e-05	0.00033	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—liver cancer	7.36e-05	0.00033	CcSEcCtD
Bortezomib—Infection—Doxorubicin—liver cancer	7.31e-05	0.000328	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—liver cancer	7.24e-05	0.000325	CcSEcCtD
Bortezomib—Shock—Doxorubicin—liver cancer	7.24e-05	0.000324	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—liver cancer	7.22e-05	0.000323	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—liver cancer	7.2e-05	0.000323	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—liver cancer	7.19e-05	0.000322	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—liver cancer	7.18e-05	0.000322	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—liver cancer	7.15e-05	0.00032	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—liver cancer	7.14e-05	0.00032	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—liver cancer	7.11e-05	0.000319	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—liver cancer	7.09e-05	0.000318	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—liver cancer	7.01e-05	0.000314	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—liver cancer	7e-05	0.000314	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—liver cancer	6.91e-05	0.00031	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—liver cancer	6.88e-05	0.000308	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—liver cancer	6.87e-05	0.000308	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—liver cancer	6.86e-05	0.000307	CcSEcCtD
Bortezomib—Pain—Epirubicin—liver cancer	6.8e-05	0.000305	CcSEcCtD
Bortezomib—Constipation—Epirubicin—liver cancer	6.8e-05	0.000305	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—liver cancer	6.7e-05	0.0003	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—liver cancer	6.65e-05	0.000298	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—liver cancer	6.61e-05	0.000296	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—liver cancer	6.56e-05	0.000294	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—liver cancer	6.55e-05	0.000294	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—liver cancer	6.5e-05	0.000291	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—liver cancer	6.48e-05	0.00029	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—liver cancer	6.4e-05	0.000287	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—liver cancer	6.35e-05	0.000285	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—liver cancer	6.34e-05	0.000284	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—liver cancer	6.32e-05	0.000283	CcSEcCtD
Bortezomib—Pain—Doxorubicin—liver cancer	6.29e-05	0.000282	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—liver cancer	6.29e-05	0.000282	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—liver cancer	6.29e-05	0.000282	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—liver cancer	6.29e-05	0.000282	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—liver cancer	6.06e-05	0.000272	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—liver cancer	6.02e-05	0.00027	CcSEcCtD
Bortezomib—Hypersensitivity—Epirubicin—liver cancer	5.86e-05	0.000263	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—liver cancer	5.84e-05	0.000262	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—liver cancer	5.82e-05	0.000261	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—liver cancer	5.82e-05	0.000261	CcSEcCtD
Bortezomib—Asthenia—Epirubicin—liver cancer	5.71e-05	0.000256	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—liver cancer	5.63e-05	0.000252	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—liver cancer	5.44e-05	0.000244	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—liver cancer	5.42e-05	0.000243	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—liver cancer	5.28e-05	0.000237	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—liver cancer	5.26e-05	0.000236	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—liver cancer	5.21e-05	0.000233	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—liver cancer	5.06e-05	0.000227	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—liver cancer	5.03e-05	0.000226	CcSEcCtD
Bortezomib—Rash—Epirubicin—liver cancer	5.01e-05	0.000225	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—liver cancer	5.01e-05	0.000225	CcSEcCtD
Bortezomib—Headache—Epirubicin—liver cancer	4.98e-05	0.000223	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—liver cancer	4.87e-05	0.000218	CcSEcCtD
Bortezomib—Nausea—Epirubicin—liver cancer	4.72e-05	0.000212	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—liver cancer	4.68e-05	0.00021	CcSEcCtD
Bortezomib—Rash—Doxorubicin—liver cancer	4.64e-05	0.000208	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—liver cancer	4.63e-05	0.000208	CcSEcCtD
Bortezomib—Headache—Doxorubicin—liver cancer	4.61e-05	0.000207	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—liver cancer	4.37e-05	0.000196	CcSEcCtD
Bortezomib—CYP2C8—Metabolism—GOT1—liver cancer	3.74e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PIK3CA—liver cancer	3.73e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—liver cancer	3.73e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.72e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1A—liver cancer	3.71e-06	1.29e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.68e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK8—liver cancer	3.68e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK8—liver cancer	3.68e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK8—liver cancer	3.68e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTP1—liver cancer	3.66e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PSMA4—liver cancer	3.66e-06	1.27e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PSMD10—liver cancer	3.66e-06	1.27e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP2E1—liver cancer	3.63e-06	1.27e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.63e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—liver cancer	3.63e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—liver cancer	3.63e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—liver cancer	3.63e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PSMD10—liver cancer	3.62e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PSMA4—liver cancer	3.62e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK8—liver cancer	3.62e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—HMOX1—liver cancer	3.61e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTA4—liver cancer	3.61e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—liver cancer	3.58e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	3.58e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GOT2—liver cancer	3.56e-06	1.24e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CG—liver cancer	3.55e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GOT2—liver cancer	3.52e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.52e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTA2—liver cancer	3.52e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—liver cancer	3.5e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—liver cancer	3.5e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—liver cancer	3.5e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PIK3CA—liver cancer	3.5e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PIK3CA—liver cancer	3.48e-06	1.21e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HPGDS—liver cancer	3.47e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PIK3CA—liver cancer	3.46e-06	1.21e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	3.45e-06	1.2e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—liver cancer	3.45e-06	1.2e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—liver cancer	3.42e-06	1.19e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—liver cancer	3.42e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYCS—liver cancer	3.4e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—liver cancer	3.4e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—liver cancer	3.39e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—liver cancer	3.39e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—liver cancer	3.39e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTA1—liver cancer	3.39e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—liver cancer	3.38e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—liver cancer	3.38e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—liver cancer	3.37e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTM1—liver cancer	3.37e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT3—liver cancer	3.36e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT3—liver cancer	3.36e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT3—liver cancer	3.36e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTP1—liver cancer	3.36e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NAT2—liver cancer	3.35e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—liver cancer	3.35e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—liver cancer	3.35e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—liver cancer	3.35e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—liver cancer	3.35e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—liver cancer	3.35e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—liver cancer	3.35e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—liver cancer	3.35e-06	1.17e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—liver cancer	3.35e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP2E1—liver cancer	3.34e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GGT1—liver cancer	3.34e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GOT1—liver cancer	3.34e-06	1.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—liver cancer	3.33e-06	1.16e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—liver cancer	3.33e-06	1.16e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—liver cancer	3.33e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP2E1—liver cancer	3.31e-06	1.15e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—liver cancer	3.31e-06	1.15e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HMOX1—liver cancer	3.31e-06	1.15e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—liver cancer	3.3e-06	1.15e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—liver cancer	3.3e-06	1.15e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—liver cancer	3.28e-06	1.14e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—liver cancer	3.24e-06	1.13e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—liver cancer	3.22e-06	1.12e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDOB—liver cancer	3.22e-06	1.12e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.21e-06	1.12e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—liver cancer	3.2e-06	1.12e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—liver cancer	3.17e-06	1.1e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—liver cancer	3.17e-06	1.1e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—liver cancer	3.17e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.15e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYCS—liver cancer	3.13e-06	1.09e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—liver cancer	3.13e-06	1.09e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—liver cancer	3.12e-06	1.09e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—liver cancer	3.12e-06	1.09e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—liver cancer	3.12e-06	1.09e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CD—liver cancer	3.12e-06	1.09e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—liver cancer	3.11e-06	1.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—liver cancer	3.11e-06	1.08e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—liver cancer	3.11e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.11e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYCS—liver cancer	3.1e-06	1.08e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—liver cancer	3.1e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PSMD10—liver cancer	3.1e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PSMA4—liver cancer	3.1e-06	1.08e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—liver cancer	3.09e-06	1.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—liver cancer	3.09e-06	1.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—liver cancer	3.09e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—liver cancer	3.09e-06	1.07e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—liver cancer	3.08e-06	1.07e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—liver cancer	3.08e-06	1.07e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—liver cancer	3.08e-06	1.07e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—liver cancer	3.07e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GGT1—liver cancer	3.07e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GOT1—liver cancer	3.07e-06	1.07e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—liver cancer	3.07e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CRABP1—liver cancer	3.07e-06	1.07e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—liver cancer	3.05e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GGT1—liver cancer	3.04e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GOT1—liver cancer	3.04e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GOT2—liver cancer	3.01e-06	1.05e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTP1—liver cancer	3e-06	1.04e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—liver cancer	2.97e-06	1.04e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HMOX1—liver cancer	2.96e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP1A1—liver cancer	2.93e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARA—liver cancer	2.92e-06	1.02e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—liver cancer	2.88e-06	1e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—liver cancer	2.88e-06	1e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—liver cancer	2.88e-06	1e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—liver cancer	2.86e-06	9.95e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—liver cancer	2.84e-06	9.9e-06	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—liver cancer	2.84e-06	9.9e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP2E1—liver cancer	2.83e-06	9.86e-06	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—liver cancer	2.83e-06	9.85e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTP1—liver cancer	2.76e-06	9.6e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—liver cancer	2.75e-06	9.59e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.74e-06	9.55e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTP1—liver cancer	2.73e-06	9.52e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—liver cancer	2.73e-06	9.5e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMOX1—liver cancer	2.72e-06	9.47e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CB—liver cancer	2.72e-06	9.47e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMOX1—liver cancer	2.7e-06	9.39e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HPGDS—liver cancer	2.68e-06	9.34e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARA—liver cancer	2.68e-06	9.32e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—liver cancer	2.65e-06	9.23e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—liver cancer	2.65e-06	9.23e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—liver cancer	2.65e-06	9.23e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYCS—liver cancer	2.65e-06	9.23e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.62e-06	9.13e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—liver cancer	2.61e-06	9.1e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP1A1—liver cancer	2.61e-06	9.09e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GGT1—liver cancer	2.6e-06	9.05e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GOT1—liver cancer	2.6e-06	9.05e-06	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—liver cancer	2.59e-06	9.02e-06	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—liver cancer	2.59e-06	9.02e-06	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—liver cancer	2.59e-06	9.02e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—liver cancer	2.56e-06	8.93e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—liver cancer	2.56e-06	8.93e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—liver cancer	2.56e-06	8.93e-06	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—liver cancer	2.55e-06	8.89e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—liver cancer	2.53e-06	8.82e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—liver cancer	2.53e-06	8.8e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—liver cancer	2.51e-06	8.75e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CG—liver cancer	2.5e-06	8.7e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—liver cancer	2.45e-06	8.54e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—liver cancer	2.45e-06	8.54e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—liver cancer	2.45e-06	8.54e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—liver cancer	2.43e-06	8.48e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—liver cancer	2.42e-06	8.42e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—liver cancer	2.41e-06	8.4e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.4e-06	8.37e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1A1—liver cancer	2.4e-06	8.36e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSMA4—liver cancer	2.39e-06	8.32e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSMD10—liver cancer	2.39e-06	8.32e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARA—liver cancer	2.39e-06	8.32e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1A1—liver cancer	2.38e-06	8.29e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—liver cancer	2.35e-06	8.17e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—liver cancer	2.35e-06	8.17e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—liver cancer	2.35e-06	8.17e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTP1—liver cancer	2.34e-06	8.13e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GOT2—liver cancer	2.32e-06	8.1e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—liver cancer	2.31e-06	8.06e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMOX1—liver cancer	2.3e-06	8.02e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CG—liver cancer	2.29e-06	7.98e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—liver cancer	2.24e-06	7.8e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—liver cancer	2.22e-06	7.73e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—liver cancer	2.21e-06	7.7e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CD—liver cancer	2.2e-06	7.65e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARA—liver cancer	2.2e-06	7.65e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2E1—liver cancer	2.19e-06	7.61e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARA—liver cancer	2.18e-06	7.58e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—liver cancer	2.17e-06	7.55e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—liver cancer	2.17e-06	7.54e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—liver cancer	2.17e-06	7.54e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—liver cancer	2.17e-06	7.54e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—liver cancer	2.15e-06	7.47e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.15e-06	7.47e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—liver cancer	2.13e-06	7.43e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CG—liver cancer	2.05e-06	7.12e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYCS—liver cancer	2.05e-06	7.12e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP1A1—liver cancer	2.03e-06	7.09e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CD—liver cancer	2.01e-06	7.02e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GOT1—liver cancer	2.01e-06	6.99e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GGT1—liver cancer	2.01e-06	6.99e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—liver cancer	1.99e-06	6.93e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—liver cancer	1.97e-06	6.87e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.96e-06	6.81e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CB—liver cancer	1.92e-06	6.67e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—liver cancer	1.9e-06	6.61e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CG—liver cancer	1.88e-06	6.55e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CG—liver cancer	1.86e-06	6.49e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARA—liver cancer	1.86e-06	6.48e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—liver cancer	1.82e-06	6.32e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTP1—liver cancer	1.8e-06	6.28e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—liver cancer	1.8e-06	6.27e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CD—liver cancer	1.8e-06	6.26e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMOX1—liver cancer	1.78e-06	6.19e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—liver cancer	1.78e-06	6.18e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CB—liver cancer	1.76e-06	6.11e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.67e-06	5.82e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—liver cancer	1.66e-06	5.77e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—liver cancer	1.66e-06	5.77e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CD—liver cancer	1.65e-06	5.76e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CD—liver cancer	1.64e-06	5.71e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—liver cancer	1.63e-06	5.69e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—liver cancer	1.62e-06	5.64e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CG—liver cancer	1.59e-06	5.55e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1A1—liver cancer	1.57e-06	5.47e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CB—liver cancer	1.57e-06	5.46e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—liver cancer	1.54e-06	5.36e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—liver cancer	1.46e-06	5.1e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CB—liver cancer	1.44e-06	5.02e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARA—liver cancer	1.44e-06	5e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CB—liver cancer	1.43e-06	4.98e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CD—liver cancer	1.4e-06	4.88e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—liver cancer	1.38e-06	4.82e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—liver cancer	1.35e-06	4.71e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CG—liver cancer	1.23e-06	4.28e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CB—liver cancer	1.22e-06	4.25e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—liver cancer	1.19e-06	4.13e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—liver cancer	1.17e-06	4.07e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CD—liver cancer	1.08e-06	3.77e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—liver cancer	1.07e-06	3.73e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—liver cancer	1.07e-06	3.72e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—liver cancer	9.55e-07	3.33e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—liver cancer	9.54e-07	3.32e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CB—liver cancer	9.42e-07	3.28e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—liver cancer	8.79e-07	3.06e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—liver cancer	8.74e-07	3.05e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—liver cancer	8.71e-07	3.03e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—liver cancer	7.8e-07	2.72e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—liver cancer	7.44e-07	2.59e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—liver cancer	7.18e-07	2.5e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—liver cancer	7.12e-07	2.48e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—liver cancer	6.08e-07	2.12e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—liver cancer	5.75e-07	2e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—liver cancer	4.69e-07	1.63e-06	CbGpPWpGaD
